Zimmer Biomet Holdings, INC. (ZBH) — SEC Filings

Q: What are the key financial highlights for Zimmer Biomet Holdings, INC.?

Key financial highlights for Zimmer Biomet Holdings, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Zimmer Biomet Holdings, INC.?

Key executives at Zimmer Biomet Holdings, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Zimmer Biomet Holdings, INC. stock?

Risk factors for Zimmer Biomet Holdings, INC. (ZBH) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Zimmer Biomet Holdings, INC.?

Forward-looking statements and predictions from Zimmer Biomet Holdings, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Zimmer Biomet Holdings, INC.. Recent ARS filing on Apr 1, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Zimmer Biomet Holdings, INC. on SEC EDGAR

Overview

Zimmer Biomet Holdings, INC. (ZBH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 1, 2026: Zimmer Biomet Holdings, Inc. filed a DEFA14A on April 1, 2026, related to additional definitive proxy soliciting materials. The filing includes various documents and graphics, with the company's mailing and business address listed as 345 East Main Street, Warsaw, IN 46580.

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 1 bullish, 37 neutral, 1 mixed. The dominant filing sentiment for Zimmer Biomet Holdings, INC. is neutral.

Filing Type Overview

Zimmer Biomet Holdings, INC. (ZBH) has filed 1 ARS, 1 DEFA14A, 6 10-Q, 21 8-K, 2 DEF 14A, 2 10-K, 3 SC 13G, 3 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (39)

ARS Filing — ARS · Apr 1, 2026
Zimmer Biomet Files Definitive Proxy Materials — DEFA14A · Apr 1, 2026 Risk: low
Zimmer Biomet Holdings, Inc. filed a DEFA14A on April 1, 2026, related to additional definitive proxy soliciting materials. The filing includes various document
Zimmer Biomet Sales Up, But Profits Squeezed by Rising Costs & M&A — 10-Q · Nov 5, 2025 Risk: medium
Zimmer Biomet Holdings, Inc. reported strong net sales growth for the three and nine months ended September 30, 2025. Net sales for the three months increased b
Zimmer Biomet Files 8-K on Debt Notes — 8-K · Oct 7, 2025 Risk: low
On October 7, 2025, Zimmer Biomet Holdings, Inc. filed an 8-K report detailing various financial events. The filing includes information about their M2.425 Note
Zimmer Biomet Files 8-K: Principal Office Location — 8-K · Sep 4, 2025 Risk: low
On September 4, 2025, Zimmer Biomet Holdings, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 345 East M
Zimmer Biomet Q2 Net Income Jumps 58% on Strong Sales Growth — 10-Q · Aug 7, 2025 Risk: medium
Zimmer Biomet Holdings, Inc. reported a 4.1% increase in net sales to $1.84 billion for the second quarter of 2025, up from $1.77 billion in the prior-year peri
Zimmer Biomet Issues Billions in New Debt — 8-K · Jul 14, 2025 Risk: medium
On July 11, 2025, Zimmer Biomet Holdings, Inc. filed an 8-K report detailing several debt issuances. These include $2.425 billion in notes due 2026, $1.164 bill
Zimmer Biomet Enters New Agreements, Terminates Others — 8-K · Jun 30, 2025 Risk: medium
On June 27, 2025, Zimmer Biomet Holdings, Inc. entered into a material definitive agreement and terminated another. The company also created a direct financial
Zimmer Biomet Files 8-K: Director Changes, Officer Appointments, Bylaw Amendments — 8-K · Jun 3, 2025 Risk: medium
Zimmer Biomet Holdings, Inc. filed an 8-K on May 29, 2025, reporting on several key events. These include the departure of directors or certain officers, the el
Zimmer Biomet Elects Directors, Appoints Officers, Discloses Notes — 8-K · May 27, 2025 Risk: medium
Zimmer Biomet Holdings, Inc. announced on May 20, 2025, the election of new directors and changes in certain officer positions. The company also disclosed compe
Zimmer Biomet Files Q1 2025 10-Q — 10-Q · May 5, 2025 Risk: low
Zimmer Biomet Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and position, including
Zimmer Biomet Files 8-K with Financial Exhibits — 8-K · Apr 21, 2025 Risk: low
On April 21, 2025, Zimmer Biomet Holdings, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific new event
Zimmer Biomet Files DEF 14A: Executive Compensation Details — DEF 14A · Apr 14, 2025 Risk: low
Zimmer Biomet Holdings, Inc. filed a DEF 14A on April 14, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending Dec
Zimmer Biomet Files 8-K: Director/Officer Changes & Compensation — 8-K · Feb 25, 2025 Risk: medium
Zimmer Biomet Holdings, Inc. filed an 8-K on February 25, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and
Zimmer Biomet Files 2024 10-K — 10-K · Feb 25, 2025 Risk: low
Zimmer Biomet Holdings, Inc. filed its 2024 10-K on February 25, 2025, reporting on its fiscal year ending December 31, 2024. The company, a leader in orthopedi
Zimmer Biomet Enters Material Definitive Agreement — 8-K · Feb 19, 2025 Risk: medium
On February 19, 2025, Zimmer Biomet Holdings, Inc. entered into a material definitive agreement related to financial obligations. The company has outstanding no
Zimmer Biomet Enters Material Definitive Agreement — 8-K · Feb 18, 2025 Risk: low
On February 11, 2025, Zimmer Biomet Holdings, Inc. entered into a material definitive agreement related to its debt. The company has outstanding notes including
Zimmer Biomet Issues $4.34B in Senior Notes — 8-K · Feb 6, 2025 Risk: medium
On February 6, 2025, Zimmer Biomet Holdings, Inc. filed an 8-K report detailing the issuance of three series of senior notes. These include $750 million in 3.51
Zimmer Biomet Files 8-K — 8-K · Jan 29, 2025 Risk: medium
Zimmer Biomet Holdings, Inc. filed an 8-K on January 29, 2025, reporting on events that occurred on January 28, 2025. The filing includes information related to
Zimmer Biomet Enters Material Definitive Agreement — 8-K · Nov 20, 2024 Risk: medium
On November 20, 2024, Zimmer Biomet Holdings, Inc. entered into a material definitive agreement related to financial obligations. The company filed an 8-K repor
Zimmer Biomet Enters Material Definitive Agreement — 8-K · Nov 19, 2024 Risk: medium
On November 13, 2024, Zimmer Biomet Holdings, Inc. entered into a material definitive agreement related to its M2.425 Notes due 2026 and M1.164 Notes due 2027.
SC 13G Filing — SC 13G · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 13, 2024
Zimmer Biomet Files Q3 2024 10-Q — 10-Q · Oct 30, 2024 Risk: low
Zimmer Biomet Holdings, Inc. filed its 10-Q for the period ending September 30, 2024. The company, headquartered at 345 East Main Street, Warsaw, IN, reported o
Zimmer Biomet Prices $1.75 Billion Debt Offering — 8-K · Aug 15, 2024 Risk: medium
On August 15, 2024, Zimmer Biomet Holdings, Inc. entered into a material definitive agreement related to the issuance of new debt. Specifically, the company ann
Zimmer Biomet Announces Debt Issuance — 8-K · Aug 14, 2024 Risk: low
Zimmer Biomet Holdings, Inc. announced on August 8, 2024, the entry into a material definitive agreement related to its debt. Specifically, the company issued "
Zimmer Biomet Files Q2 2024 10-Q — 10-Q · Aug 7, 2024 Risk: low
Zimmer Biomet Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial performance and position, including
Zimmer Biomet Enters New Debt Agreements, Terminates Old — 8-K · Jul 1, 2024 Risk: medium
On June 28, 2024, Zimmer Biomet Holdings, Inc. entered into a material definitive agreement related to its M2.425 Notes Due 2026 and M1.164 Notes Due 2027. The
Zimmer Biomet Announces Board and Executive Changes — 8-K · Jun 20, 2024 Risk: low
Zimmer Biomet Holdings, Inc. announced on June 20, 2024, changes in its board of directors and executive compensation. Specifically, the company elected new dir
Zimmer Biomet Announces Director Elections & Officer Compensation Changes — 8-K · May 15, 2024 Risk: low
Zimmer Biomet Holdings, Inc. announced on May 10, 2024, the election of new directors and changes in officer compensation. The company also reported on the subm
Zimmer Biomet Holdings, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: low
ZIMMER BIOMET HOLDINGS, INC. (ZBH) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Zimmer Biomet Holdings, Inc. filed a 10-Q report for the period
Zimmer Biomet Holdings, Inc. Files Definitive Proxy Statement — DEF 14A · Mar 27, 2024 Risk: low
ZIMMER BIOMET HOLDINGS, INC. (ZBH) filed a Proxy Statement (DEF 14A) with the SEC on March 27, 2024. Zimmer Biomet Holdings, Inc. filed a Definitive Proxy State
Zimmer Biomet Holdings, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 23, 2024 Risk: medium
ZIMMER BIOMET HOLDINGS, INC. (ZBH) filed a Annual Report (10-K) with the SEC on February 23, 2024. Zimmer Biomet Holdings, Inc. filed its annual report on Form
SC 13G Filing — SC 13G · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 13, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
Zimmer Biomet Files 8-K on Financial Results & Condition — 8-K · Feb 8, 2024 Risk: low
Zimmer Biomet Holdings, Inc. filed an 8-K on February 8, 2024, to report its financial results and condition, specifically mentioning its 1.164% Notes due 2027
BlackRock Updates ZBH Stake in SC 13G/A Filing — SC 13G/A · Jan 25, 2024
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating its ownership of ZIMMER BIOMET HOLDINGS, INC. (ZBH) common stock as of December 31, 202
Zimmer Biomet 8-K: Officer/Director Changes, Comp Arrangements — 8-K · Jan 5, 2024
Zimmer Biomet Holdings, Inc. filed an 8-K on January 5, 2024, to report on the departure or election of certain officers and directors, as well as compensatory

Risk Profile

Risk Assessment: Of ZBH's 31 recent filings, 0 were flagged as high-risk, 15 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Zimmer Biomet Holdings, INC.'s most recent 10-Q filing (Nov 5, 2025):

Revenue: $5,987.7M
Net Income: $565.8M
EPS: $2.84
Total Debt: $7,512.6M

Key Executives

Ivan Tornos
Sang Yi
Mark Bezjak
Mr. Hanson

Industry Context

The medical device industry, particularly in orthopedics, is characterized by intense competition, rapid technological advancements, and significant regulatory oversight. Companies like Zimmer Biomet must continuously innovate and invest in R&D to maintain market share and develop next-generation products. Consolidation through mergers and acquisitions is also a common strategy to expand product portfolios and geographic reach.

Top Tags

financing (7) · debt (6) · financials (5) · Orthopedics (4) · notes (4) · debt-issuance (4) · corporate-governance (4) · 10-Q (4) · Medical Devices (3) · executive-compensation (3)

Key Numbers

Net Sales (Q3 2025): $2,001.4M — Up 9.7% from $1,824.2M in Q3 2024
Net Sales (9 Months 2025): $5,987.7M — Up 5.9% from $5,655.4M in 9 Months 2024
Net Earnings (Q3 2025): $230.9M — Down 7.3% from $249.1M in Q3 2024
Net Earnings (9 Months 2025): $565.8M — Down 14.8% from $664.3M in 9 Months 2024
Diluted EPS (Q3 2025): $1.16 — Down from $1.23 in Q3 2024
Diluted EPS (9 Months 2025): $2.84 — Down from $3.24 in 9 Months 2024
Interest Expense, net (Q3 2025): $75.4M — Increased from $54.3M in Q3 2024
Business Combination Investments (9 Months 2025): $1,226.3M — Significantly up from $116.3M in 9 Months 2024
2025 Restructuring Plan Estimated Charges: $85M — Total pre-tax charges expected by end of 2027
Long-term Debt (Sept 30, 2025): $7,512.6M — Increased from $5,341.6M at Dec 31, 2024
Maturity Year: 2026 — M2.425 Notes
Net Sales: $1.84B — Increased 4.1% from $1.77B in Q2 2024
Net Income: $238.6M — Increased 58.6% from $150.4M in Q2 2024
Diluted EPS: $1.14 — Increased from $0.72 in Q2 2024
Restructuring Charges: $10.0M — Incurred for 2025 Restructuring Plan

Forward-Looking Statements

{"claim":"Zimmer Biomet's stock price will remain stable as this is a routine financial disclosure.","entity":"ZIMMER BIOMET HOLDINGS, INC.","targetDate":"2024-03-08","confidence":"high"}
{"claim":"Analysts will incorporate the new financial condition data into their models for ZBH.","entity":"ZIMMER BIOMET HOLDINGS, INC.","targetDate":"2024-02-22","confidence":"high"}

Related Companies

SYK · JNJ

Frequently Asked Questions

What are the latest SEC filings for Zimmer Biomet Holdings, INC. (ZBH)?

Zimmer Biomet Holdings, INC. has 39 recent SEC filings from Jan 2024 to Apr 2026, including 21 8-K, 6 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of ZBH filings?

Across 39 filings, the sentiment breakdown is: 1 bullish, 37 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Zimmer Biomet Holdings, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Zimmer Biomet Holdings, INC. (ZBH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Zimmer Biomet Holdings, INC.?

Key financial highlights from Zimmer Biomet Holdings, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for ZBH?

The investment thesis for ZBH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Zimmer Biomet Holdings, INC.?

Key executives identified across Zimmer Biomet Holdings, INC.'s filings include Ivan Tornos, Sang Yi, Mark Bezjak, Mr. Hanson.

What are the main risk factors for Zimmer Biomet Holdings, INC. stock?

Of ZBH's 31 assessed filings, 0 were flagged high-risk, 15 medium-risk, and 16 low-risk.

What are recent predictions and forward guidance from Zimmer Biomet Holdings, INC.?

Recent forward-looking statements from Zimmer Biomet Holdings, INC. include guidance on {"claim":"Zimmer Biomet's stock price will remain stable as this is a routine financial disclosure.","entity":"ZIMMER BI and 1 other predictions.